Anika Therapeutics, Inc.: operating_income
| Value | {"amount": 844000, "concept": "us-gaap:OperatingIncomeLoss", "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-12-31 |
| Status | current |
| Entity | Anika Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T09:02:51.542883+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/dfeb5fa5-7539-489c-99e8-c89183624386
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001171843-25-001486Retrieved: 2026-08-19T09:02:51.542883+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0000898437/operating-income/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/dfeb5fa5-7539-489c-99e8-c89183624386
History
- supersedes {"amount": -87639000, "concept": "us-gaap:OperatingIncomeLoss", "currency": "USD"} (evidence 0001171843-24-001380)